cemiplimab+fianlimab

Phase 2Monoclonal antibody

UUniversity of Chicago

cemiplimab+fianlimab is one of 73 small molecule programs targeting Melanoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MelanomaActive, not recruiting

PapillomaActive, not recruiting

MelanomaPhase 2

Active, not recruiting

PapillomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

947 competitors in Melanoma

#DrugCompanyPhaseTrials

ABI-007

Bristol-Myers Squibb

Phase 3

1 2

Rhuph20

Bristol-Myers Squibb

Phase 3

1 3

ABP 234

Amgen

Phase 3

1 4

Actimmune

HHorizon Therapeutics Ireland DAC

Interferon-Gamma

1 6

Tumor Necrosis Factor

NNational Cancer Institute (NCI)

Phase 3

1 7

IBI308

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

1 8

Zelboraf

CConrado Roberto Hoffmann Filho

Preclinical

39 9

BCD-217

BBiocad

Phase 3

1 10

Intron a

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Recruiting

Melanoma

NCT06887088

Q4 2029

Phase 2Not yet recruiting

Papilloma

NCT07179315

Clinical

Trials by Indication[1]

Papilloma1 trial

A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Treatment

Not yet recruiting·UUniversity of Chicago·Phase 2·NCT07179315·68 enrolled

Melanoma1 trial

Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases

Recruiting·GGrupo Español Multidisciplinar de Melanoma·Phase 2·NCT06887088·33 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for cemiplimab+fianlimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — cemiplimab+fianlimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for cemiplimab+fianlimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Chicago company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Chicago

cemiplimab+fianlimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q4 2029

Trials by Indication[1]

Papilloma1 trial

Melanoma1 trial

References

Drug Info

Quick Facts

Related News